News for Foghorn Therapeutics Inc. (FHTX)

Foghorn Therapeutics (FHTX) has retained its favorable standing among analysts as JMP Securities continues to express confidence in the company's potential. On

Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of 0% and 10.04%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

As of the end of the first quarter in 2025, FHTX reported holding $220.6 million in cash, cash equivalents, and marketable securities. This financial position i

Foghorn Therapeutics (FHTX) reported first-quarter revenue of $5.9 million, surpassing the consensus estimate of $4.97 million. The company is making significan

**media[625375]**

CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. ( FHTX), a clinical-stage biotechnology company pioneering a new class of medic

CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. ( FHTX), a clinical-stage biotechnology company pioneering a new class of medic

Foghorn Therapeutics (FHTX) recently presented compelling preclinical findings at the 2025 American Association for Cancer Research meeting. Key highlights incl

- FHD-909 (LY4050784) advancing in Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Citizens JMP has initiated coverage of Foghorn Therapeutics (FHTX), assigning it an Outperform rating coupled with a $9 price target. Foghorn Therapeutics, a cl

Foghorn Therapeutics (FHTX) plans a virtual investor event on April 29, 2025. New preclinical data for FHD-909, a selective SMARCA2 inhibitor, will be p

Shares of PVH Corp. PVH rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results. Calvin Kle...

Shares of PVH Corp. PVH rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results. Calvin Kle...

Foghorn Therapeutics advances FHD-909 for SMARCA4 tumors, backed by Eli Lilly partnership. Read here to know why we are neutral on FHTX stock.

**media[576518]**

Charles River Laboratories International, Inc. (NYSE: CRL) and Valo Health, Inc. today announced the identification of an advanceable product candidate for the

[url=

Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of -3.45% and 75.63%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?